An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a standard flu shot, the company announced this week.

Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu shot in adults aged 50 years and older in a late-stage study. Shares of the company were up 5.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE,